Enterin Inc.

3624 Market Street
Suite 517
Philadelphia
Pennsylvania
19104
United States

About Enterin Inc.

Enterin is pioneering the medical community’s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease.
We are leveraging years of research to become the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease.
Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha- synuclein (aS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson’s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson’s disease.
Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis.
YEAR FOUNDED:
2016
LEADERSHIP:
Founder, Chairman & CEO: Michael Zasloff, MD, PhD
Co-founder, President & CMO: Denise Barbut, MD, FRCP
Co-Founder, Senior VP, R&D: William Kinney, PhD
CFO: Nancy Ness
Senior Advisor, Regulatory Affairs: Brian Harvey, MD, PhD
SCIENCE:
Please click here for Enterin's science.

10 articles about Enterin Inc.

WILLOW ANNOUNCES COLLABORATION WITH ENTERIN TO DEVELOP SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS

1/16/2024

Willow Biosciences Inc. today announced a collaboration with Enterin, Inc. to develop new sustainable manufacturing routes to their key intermediates and active pharmaceutical ingredients (APIs).
Enterin Presents Data Demonstrating Strong Benefit of ENT-03 on Body Weight, Adiposity and Blood Glucose Vs. Semaglutide in a Diet Induced Obesity Mouse ModelData presented at the American Diabetes Association 83rd Scientific Sessions

6/24/2023

Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and metabolic diseases, presented in vivo data demonstrating benefit on body weight, adiposity and blood glucose of ENT-03 compared to semaglutide in an obese, diabetic animal model, with persistence of benefit on weight beyond treatment.
Enterin Announces the Start of a First-in-Human Study of ENT-03 in Obesity and Type 2 Diabetes

6/5/2023

Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company pioneering novel treatments for neurodegenerative and metabolic diseases, today announced the start of a Phase 1a study in obesity and Type 2 diabetes (IND #155001).
Enterin and Parkinson’s UK Announce Research Collaboration in Parkinson’s Dementia

10/13/2022

Enterin Inc. announces a collaboration with the Parkinson’s Virtual Biotech, the drug development and discovery arm of Parkinson's UK. A new phase 2 trial will study the effects of ENT-01 on Parkinson’s Disease -associated dementia.
Enterin Announces New Funding and Appointment of David Vogel to Its Board of Directors

10/3/2022

Enterin Inc., a privately held, Philadelphia-based, clinical-stage biopharmaceutical company developing novel treatments for neurodegenerative and metabolic diseases, announces that David Vogel has joined the Board of Directors.
Enterin's RASMET Study Published

8/28/2019

Enterin Inc. announces the publication of its Phase 2a RASMET study.
Enterin's DEMET Study Enrolls First Patient With Parkinson's Disease Dementia (PDD)

6/24/2019

Enterin Inc., a CNS pharmaceutical company based in Philadelphia and developing novel compounds to treat Parkinson’s disease, has enrolled the first patient in the DEMET study.
Enterin Raises $12.7 Million In Series A Financing

7/17/2017
Founders Of Philadelphia Biotech Enterin Discover Link Between Upper GI Tract Infections And Parkinson's Disease

6/29/2017
Enterin's RASMET Study Enrolls First Patient With Parkinson's Disease

5/16/2017